Get the Stockscreener App
2.20
0.92%
0.02
Aytu Biopharma Inc stock is traded at $2.20, with a volume of 93,622.
It is up +0.92% in the last 24 hours and down -13.89% over the past month.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
See More
Previous Close:
$2.18
Open:
$2.22
24h Volume:
93,622
Relative Volume:
0.26
Market Cap:
$19.75M
Revenue:
$93.76M
Net Income/Loss:
$-13.68M
P/E Ratio:
-0.8365
EPS:
-2.63
Net Cash Flow:
$8.77M
1W Performance:
-0.45%
1M Performance:
-13.89%
6M Performance:
+62.96%
1Y Performance:
-10.93%
1-Day Range:
$2.174
$2.28
1-Week Range:
$2.1052
$2.28
52-Week Range:
$0.95
$2.85
Aytu Biopharma Inc Stock (AYTU) Company Profile
Name
Aytu Biopharma Inc
Sector
Phone
(720) 437-6580
Address
7900 E. UNION AVENUE, DENVER
Compare AYTU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.20 | 19.75M | 93.76M | -13.68M | 8.77M | -2.63 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Initiated | Lake Street | Buy |
| Jun-30-25 | Initiated | Ascendiant Capital Markets | Buy |
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-29-20 | Initiated | H.C. Wainwright | Buy |
Aytu Biopharma Inc Stock (AYTU) Latest News
What to do if you’re stuck in Aytu BioPharma Inc.2025 Key Highlights & Consistent Return Investment Signals - Newser
Aytu BioPharma Inc. Attempts Reversal From Key SupportTrade Risk Assessment & Weekly Breakout Opportunity Watchlist - thegnnews.com
Detecting support and resistance levels for Aytu BioPharma Inc.Quarterly Risk Review & Safe Capital Growth Trade Ideas - Newser
Analyzing Aytu BioPharma Inc. with risk reward ratio chartsBull Run & Growth-Oriented Investment Plans - Newser
What machine learning models say about Aytu BioPharma Inc.2025 Price Targets & Verified Chart Pattern Signals - Newser
Will breakout in Aytu BioPharma Inc. lead to full recoveryWeekly Risk Summary & Precise Swing Trade Alerts - Newser
What data driven models say about Aytu BioPharma Inc.’s future2025 Support & Resistance & Advanced Technical Signal Analysis - Newser
Multi asset correlation models including Aytu BioPharma Inc.Market Growth Summary & Weekly Setup with High ROI Potential - Newser
Using Python tools to backtest Aytu BioPharma Inc. strategiesJuly 2025 Market Mood & Real-Time Chart Pattern Alerts - Newser
Aytu BioPharma Inc. stock daily chart insightsEntry Point & High Conviction Buy Zone Picks - Newser
Should I average down on Aytu BioPharma Inc. stock2025 Top Decliners & Trade Opportunity Analysis - classian.co.kr
How hedge fund analytics apply to Aytu BioPharma Inc. stockJuly 2025 Outlook & Intraday High Probability Setup Alerts - Newser
What recovery options are there for Aytu BioPharma Inc.2025 Historical Comparison & AI Enhanced Execution Alerts - Newser
Why Aytu BioPharma Inc. stock attracts strong analyst attentionPortfolio Return Report & Free Reliable Trade Execution Plans - Newser
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Path To Profitability - Yahoo Finance
Will Aytu BioPharma Inc. see short term momentum2025 Historical Comparison & Advanced Swing Trade Entry Plans - Newser
What the charts say about Aytu BioPharma Inc. todayMarket Activity Summary & Daily Momentum Trading Reports - Newser
How to recover losses in Aytu BioPharma Inc. stockTrade Risk Summary & Risk Controlled Stock Pick Alerts - Newser
Combining price and volume data for Aytu BioPharma Inc.Earnings Overview Summary & Real-Time Chart Pattern Alerts - Newser
Can trapped investors hope for a rebound in Aytu BioPharma Inc.Portfolio Update Report & Fast Momentum Stock Entry Tips - Newser
Will Aytu BioPharma Inc. stock recover after recent dropPortfolio Value Summary & Consistent Income Trade Recommendations - Newser
Live market analysis of Aytu BioPharma Inc.July 2025 Action & AI Enhanced Trading Signals - Newser
Will Aytu BioPharma Inc. outperform the market2025 Support & Resistance & Weekly Chart Analysis and Trade Guides - Newser
Full technical analysis of Aytu BioPharma Inc. stockMarket Growth Review & Pattern Based Trade Signal System - Newser
Can Aytu BioPharma Inc. benefit from deglobalizationFast ROI Stock Opportunities - thegnnews.com
Aytu Biopharma Inc Stock (AYTU) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aytu Biopharma Inc Stock (AYTU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Disbrow Joshua R. | Chief Executive Officer |
Jun 09 '25 |
Buy |
1.50 |
66,666 |
99,999 |
153,257 |
| Disbrow Joshua R. | Chief Executive Officer |
Feb 28 '25 |
Buy |
1.30 |
15,000 |
19,500 |
86,591 |
2.37%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):